文献速递肝病消化道肿瘤与早癌

TERT基因变异改变酒精性肝硬化患者肝细胞癌风险:全基因组病例对照研究结果

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
PubMed 文献 · Gut · 2022-07-04

本研究在德国、奥地利、瑞士、意大利和英国纳入酒精性肝硬化伴肝细胞癌病例1214例和无肝细胞癌对照1866例,开展两阶段全基因组关联研究。结果显示PNPLA3 rs738409和TM6SF2 rs58542926与肝细胞癌风险增加相关获全基因组显著性验证,TERT rs2242652(A)与肝细胞癌风险降低相关(p=6.41×10-9,OR=0.61,95%CI 0.52-0.70)。

要点

  • PNPLA3 rs738409和TM6SF2 rs58542926与酒精性肝硬化患者肝细胞癌风险增加相关获验证。
  • TERT rs2242652(A)与肝细胞癌风险降低相关,校正混杂因素后仍显著。
  • 携带TERT rs2242652(A)与白细胞端粒长度增加相关。

核心结论

  • 本研究识别出TERT rs2242652是酒精性肝硬化患者肝细胞癌的新型保护因素。

研究设计与样本

  • 两阶段全基因组关联研究,采用病例对照设计,病例为酒精性肝硬化伴肝细胞癌患者(n=1214),对照为无肝细胞癌的酒精性肝硬化患者(n=1866),来自德国、奥地利、瑞士、意大利和英国。
  • 另纳入1520例有酒精滥用但无肝病证据者作为验证队列,以控制酒精滥用可能带来的关联效应。
  • 基因分型使用InfiniumGlobal Screening Array(V.24v2,Illumina)和OmniExpress Array(V.24v1-0a,Illumina)。

主要发现

  • PNPLA3 rs738409和TM6SF2 rs58542926与酒精性肝硬化患者肝细胞癌风险增加相关,在全基因组显著性水平得到验证。
  • 在合并荟萃分析中,TERT rs2242652(A)与肝细胞癌风险降低相关,达全基因组显著性(p=6.41×10-9,OR=0.61,95%CI 0.52-0.70)。
  • 校正性别、年龄、体重指数和2型糖尿病后,该保护性关联仍显著(p=7.94×10-5,OR=0.63,95%CI 0.50-0.79)。
  • 携带TERT rs2242652(A)与白细胞端粒长度增加相关(p=2.12×10-44)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence. This study aimed to identify novel susceptibility loci for the development of HCC in people with alcohol related cirrhosis. DESIGN: Patients with alcohol-related cirrhosis and HCC (cases: n=1214) and controls without HCC (n=1866), recruited from Germany, Austria, Switzerland, Italy and the UK, were included in a two-stage genome-wide association study using a case-control design. A validation cohort of 1520 people misusing alcohol but with no evidence of liver disease was included to control for possible association effects with alcohol misuse. Genotyping was performed using the InfiniumGlobal Screening Array (V.24v2, Illumina) and the OmniExpress Array (V.24v1-0a, Illumina). RESULTS: Associations with variants rs738409 in PNPLA3 and rs58542926 in TM6SF2 previously associated with an increased risk of HCC in patients with alcohol-related cirrhosis were confirmed at genome-wide significance. A novel locus rs2242652(A) in TERT (telomerase reverse transcriptase) was also associated with a decreased risk of HCC, in the combined meta-analysis, at genome-wide significance (p=6.41×10-9, OR=0.61 (95% CI 0.52 to 0.70). This protective association remained significant after correction for sex, age, body mass index and type 2 diabetes (p=7.94×10-5, OR=0.63 (95% CI 0.50 to 0.79). Carriage of rs2242652(A) in TERT was associated with an increased leucocyte telomere length (p=2.12×10-44). CONCLUSION: This study identifies rs2242652 in TERT as a novel protective factor for HCC in patients with alcohol-related cirrhosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Buch S, Innes H, Lutz PL, et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut. 2022. PMID: 35788059. doi:10.1136/gutjnl-2022-327196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。